Metagenomi Therapeutics financials
$1.13−0.88%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $25.2M | $52.3M |
| Gross profit | $25.2M | $52.3M |
| Gross margin | 100.0% | 100.0% |
| Operating income | -$96.0M | -$88.9M |
| Net income | -$87.9M | -$78.1M |
| Net margin | −348.5% | −149.3% |
| Diluted EPS | $-2.36 | $-2.36 |
| EBITDA | -$90.7M | -$83.5M |
| Operating cash flow | -$88.9M | -$109.1M |
| Free cash flow | -$89.5M | -$112.2M |
| Diluted shares | 37.3M | 33.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $41.7M | $27.4M |
| Short-term investments | $119.1M | $220.9M |
| Total debt | $0.00 | $0.00 |
| Total assets | $221.1M | $324.6M |
| Total liabilities | $62.5M | $89.7M |
| Shareholders' equity | $158.6M | $234.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology